Erythropoietin-Modified Mesenchymal Stem Cells Enhance Antifibrosis Efficacy in Mouse Liver Fibrosis Model
10.1007/s13770-020-00276-2
- Author:
Xianyao WANG
1
;
Huizhen WANG
;
Junhou LU
;
Zhanhui FENG
;
Zhongshan LIU
;
Hailiang SONG
;
Heng WANG
;
Yanhua ZHOU
;
Jianwei XU
Author Information
1. National Guizhou Joint Engineering Laboratory for Cell Engineering and Biomedicine Technique/Center for Tissue Engineering and Stem Cell Research/Guizhou Province Key Laboratory of Regenerative Medicine, Guizhou Medical University, Beijing Road 9, Guiyang 550004, Guizhou Province, China
- Publication Type:O RI G I N A L A R T I C L E
- From:
Tissue Engineering and Regenerative Medicine
2020;17(5):683-693
- CountryRepublic of Korea
- Language:English
-
Abstract:
BACKGROUND:Mesenchymal stem cell (MSC)-based cell transplantation is an effective means of treating chronic liver injury, fibrosis and end-stage liver disease. However, extensive studies have found that only a small number of transplanted cells migrate to the site of injury or lesion, and repair efficacy is very limited.
METHODS:Bone marrow-derived MSCs (BM-MSCs) were generated that overexpressed the erythropoietin (EPO) gene using a lentivirus. Cell Counting Kit-8 was used to detect the viability of BM-MSCs after overexpressing EPO. Cell migration and apoptosis were verified using Boyden chamber and flow cytometry, respectively. Finally, the anti-fibrosis efficacy of EPO-MSCs was evaluated in vivo using immunohistochemical analysis.
RESULTS:EPO overexpression promoted cell viability and migration of BM-MSCs without inducing apoptosis, and EPO-MSC treatment significantly alleviated liver fibrosis in a carbon tetrachloride (CCl4 ) induced mouse liver fibrosis model.
CONCLUSION:EPO-MSCs enhance anti-fibrotic efficacy, with higher cell viability and stronger migration ability compared with treatment with BM-MSCs only. These findings support improving the efficiency of MSCs transplantation as a potential therapeutic strategy for liver fibrosis.
